A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Latest Information Update: 21 Oct 2024
Price :
$35 *
At a glance
- Drugs Adimlecleucel (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- Sponsors Atara Biotherapeutics
- 09 Jul 2024 Status changed from recruiting to completed.
- 01 Jul 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.
- 01 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2024.